Valeritas gives up controlling interest for $150M round

Bridgewater, NJ-based Valeritas has rounded up a whopping $150 million C round to finance the commercialization of a disposable insulin delivery device for diabetics. Welsh, Carson, Anderson & Stowe led the financing and grabbed a controlling interest in Valeritas. "Millions of adult patients suffer from Type 2 diabetes and require insulin, and we believe the V-Go will be an important treatment option to assist in the management of their diabetes," says Valeritas CEO Kristine Peterson. Report | Valeritas release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.